Rare mutation may predict strong immunotherapy response in colorectal cancer

A new study led by researchers at The University of Texas MD Anderson Cancer Center shows that a specific subset of mutations in the POLE gene is strongly associated with durable responses to immunotherapy in patients with metastatic colorectal cancer (CRC).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup